BioPharmSignal logoBioPharmSignal

Biotech News

TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial

TC BioPharm (TCBP)TC BioPharmClinical readout

TCBP (TCBP) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is tcbp.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

BMEABiomea Fusion2026-08-24 11:00 EST

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

COGTCogent Biosciences2026-06-12 12:00 EST

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

SNDXSyndax Pharmaceuticals2026-06-11 11:03 EST

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

View all latest news

TC BioPharm

TC BioPharm is a cell-therapy biotechnology company focused on gamma delta T-cell approaches for cancer and related immune applications. Its story is built around a narrow platform that tries to create differentiated anti-cancer activity through engineered immune cells.

Recent company news

TCBPTC BioPharm2025-06-11 12:30 EST

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

TCBPTC BioPharm2025-04-09 13:00 EST

TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells

TCBPTC BioPharm2025-03-21 14:45 EST

TCBP Announces Transition from Nasdaq to OTC Markets

TCBPTC BioPharm2025-03-18 12:03 EST

TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead

TCBPTC BioPharm2025-03-05 13:30 EST

TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States